AstraZeneca has officially changed the name of its COVID-19 vaccine
AstraZeneca has now registered the brand name Vaxzevria for its COVID-19 vaccine.
The TGA approved the name change on Thursday for the product previously named COVID-19 Vaccine AstraZeneca.
It is estimated that supply in Australia of the Vaxzevria-branded product will commence in late 2021.
Once supply of the vaccine commences under the new name, the vaccine will no longer be supplied under the original name, said the TGA.
However some stock with the original name may still be in use after the name change.
In Australia, people can expect to see both names, Vaxzevria and COVID-19 Vaccine AstraZeneca, used for the coming months.
“The change to a permanent trade name has been planned for many months, and has no impact on the vaccine’s approval status, supply and delivery timings, or AstraZeneca’s commitment to provide broad and equitable access to the vaccine at no profit during the pandemic period,” said AstraZeneca in a statement.
The name change means it is now consistent with that used overseas, including in the European Union, the UK and Canada.
“Use of the Vaxzevria brand name should help simplify international travel for people vaccinated with AstraZeneca’s vaccine,” said AstraZeneca.
“The vaccine has previously received emergency authorisation from the World Health Organization. As such Vaxzevria, including Vaxzevria produced at CSL in Australia, is a valid vaccination for travel to Europe.”
Both AstraZeneca and the TGA emphasised that despite the name change, the product remains the same.
“All other aspects, such as manufacturing and quality control, are unchanged and align with the way the vaccine is produced in other jurisdictions,” said the TGA.
AstraZeneca said its COVID-19 vaccine is the same product wherever it is made.
“All manufacturing around the world is conducted using the same stringent manufacturing process and each batch passes over 60 quality tests as part of our global robust quality assurance process,” it said.